Current events within the military and professional sports have resulted in an increased recognition of the long-term and debilitating consequences of traumatic brain injury. Mild traumatic brain injury accounts for the majority of head injuries, and posttraumatic headache is the most common adverse effect. It is estimated that between 30% to 90% of traumatic brain injuries result in posttraumatic headache, and for a significant number of people this headache disorder can continue for up to and over a year post injury. Often, the most severe and chronic posttraumatic headache has a migraine-like phenotype and is difficult to resolve. In this review we discuss the preclinical findings from animal models of posttraumatic headache. We also describe potential mechanisms by which traumatic brain injury leads to chronic posttraumatic headache, including neuroinflammatory mediators and migraine-associated neuropeptides. There are surprisingly few preclinical studies that have investigated overlapping mechanisms between posttraumatic headache and migraine, especially considering the prevalence and debilitating nature of posttraumatic headache. Given this context, posttraumatic headache is a field with many emerging opportunities for growth. The frequency of posttraumatic headache in the general and military population is rising, and further preclinical research is required to understand, ameliorate, and treat this disabling disorder. V C 2017 Wiley Periodicals, Inc.
INTRODUCTION
The debilitating and often tragic consequences of traumatic brain injuries (TBIs) have received heightened and overdue attention following high-profile cases from both the military and professional sports. Consisting of blows, blasts, and jolts, TBIs are penetrating injuries to the head that disrupt normal functioning of the brain for any period of time (Gerberding and Binder, 2003) . TBIs are a serious public health concern worldwide and can often lead to persistent and disabling neuropsychological disorders. Globally, TBI is the leading cause of chronic disability among young adults and children (Feigin et al., 2013; Theeler et al., 2013) . In the United States, the incidence of TBI has particularly risen in army personnel, increasing fourfold since 2005, primarily due to combat in Iraq and Afghanistan (Theeler et al., 2013) . With the improvement of protective gear and safety standards employed in modern combat, individuals are now surviving TBIs but consequently experiencing unprecedented adverse effects (Terri Tanielian, 2008) .
Mild TBI (mTBI), which is synonymous with concussion, is the most prevalent form of head trauma, and posttraumatic headache (PTH) is the most common symptom of mTBI. The incidence of PTH is highest following mTBI and is less frequently observed following moderate or severe TBI (Nampiaparampil, 2008; Hoffman et al., 2011; Lucas et al., 2012; Theeler et al., 2013) . Up to 90% of patients with mTBI have been reported to suffer from PTH, which can persist in a subset of patients for over a year post injury (Couch and Bearss, 2001; Okie, 2005; Nampiaparampil, 2008; Hoffman et al., 2011; Lieba-Samal et al., 2011; Lucas et al., 2012) . Chronic PTH is defined by the International Classification of Headache Disorder (ICHD-3 beta version) as a secondary headache disorder, one that develops within 7 days of TBI or within 7 days after regaining consciousness from a TBI (ICHD, 2013) . While acute PTH is resolved within 3 months, persistent PTH is observed beyond this time frame. The persistence of PTH long after tissue healing suggests that some form of central sensitization and neuroadaptation has occurred. Often, the most severe and long-lasting PTHs have a migraine phenotype (Hoffman et al., 2011; Theeler et al., 2013) , and migraine-like PTH is associated with greater cognitive impairment and increased recovery time. There is a large number of civilians, veterans, and active duty military personnel suffering from PTH, and this has important implications for longterm health outcomes and quality of life. In this review we provide an overview of the epidemiology of PTH, current research models, and molecular mechanisms underlying this disorder.
Epidemiology of PTH
TBI-related emergency department visits are increasing annually. According to the Centers for Disease Control, at least 1.7 million TBI cases occur every year in the United States (Gerberding and Binder, 2003; Faul et al., 2010; Lucas, 2015) . Furthermore, more than 2 million emergency room visits are made annually due to TBI (Coronado et al., 2012) . In the general population, mTBI is most commonly due to falls, motor vehicle accidents, occupational hazards, recreational accidents, and assaults (Faul et al., 2010; D'Onofrio et al., 2014) . Thus far, the only factors that predict the development of PTH following mTBI include female sex, prior headache disorder, and a family history of headache disorders (Mihalik et al., 2013; Walker et al., 2013) . PTH is observed in 30% to 90% of cases following mTBI, and 20% to 60% continue to suffer from this disorder for a year or longer post injury (Couch and Bearss, 2001; Lucas et al., 2014) .
The incidence of TBI within the US military has dramatically increased in the last 10 years, and it has become a signature injury of the Middle East conflicts (Theeler et al., 2013) . Advancements in protective gear now allow military personnel to withstand blast injuries that would have once been fatal (Terri Tanielian, 2008) . These advancements have also increased TBI-related side effects. Recent studies show that up to 78% of soldiers returning from combat with deployment-related TBI suffered from episodic headache, and 20% from chronic daily headache (Theeler et al., 2013) . In the military population, PTH is a residual consequence of 67% of blastinduced TBI (bTBI) cases (Cernak and NobleHaeusslein, 2010; D'Onofrio et al., 2014) , and 77% of soldiers with chronic PTH experienced bTBI (Erickson, 2011) . Military-related TBI is distinct from civilian TBI, often occurring in combat-related deployment (Terri Tanielian, 2008; Theeler et al., 2010) , where additional factors such as irregular sleep patterns and emotional/psychological extremes can contribute to PTH development (Theeler et al., 2013) . The relationship between posttraumatic stress disorder (PTSD) and PTH is of particular relevance to the military population. For instance, longitudinal studies found that people with PTSD were more likely to report chronic or worsening PTH 1 year post TBI (Sawyer et al., 2015; Tschiffely et al., 2015) . Further research is required to fully understand the interplay between acute stress reactions, chronic psychiatric conditions such as PTSD, and the development and chronicity of PTH.
Treatment Strategies for PTH
To date, there are no specific pharmacological treatments for PTH. To the best of our knowledge, there has also never been a large-scale clinical trial to test treatments for PTH specifically (Monteith and Borsook, 2014) . Because of the suboptimal diagnoses and treatment of PTH, many individuals turn to over-the-counter pain medications to self-treat their headaches. Pharmacotherapy is also based on the treatment strategy used for the primary headache condition the PTH most resembles (e.g., migraine, tension-type headache). A small retrospective analysis in 167 patients found that more than 70% of nonmilitary individuals with PTH used acetaminophen or a nonsteroidal anti-inflammatory drug for headache control, while only 8% used triptans (DiTommaso et al., 2014) . Only 26% of individuals with PTH of a migraine phenotype reported complete relief, leaving 74% of individuals still suffering from PTH (DiTommaso et al., 2014) . Interestingly, a retrospective cohort study in 100 soldiers undergoing treatment for chronic PTH found that acute and preventive migraine therapies were effective treatment strategies, with triptans significantly aborting PTH, and topiramate acting as a preventive (Erickson, 2011) .
Alternative treatments have been proposed for the treatment of PTH and warrant further study. A small retrospective cohort study evaluated the therapeutic effects of onabotulinum toxin A for treatment of PTH (Yerry et al., 2015) . Although a majority of soldiers reported feeling better, many ultimately stopped treatment for lack of continued progress (Yerry et al., 2015) . Noninvasive therapy was also recently tested for the management of PTH (Leung et al., 2016) . Repetitive transcranial magnetic stimulation (rTMS) is used to treat major depressive disorder and is currently being investigated for pain management. In a small study, 24 patients suffering from PTH received rTMS or sham stimulation, and a significant reduction in headache intensity was observed in the rTMS group, which persisted 4 weeks post treatment (Leung et al., 2016) . In addition, adjunct behavioral therapies may be beneficial to PTH patients, particularly to supplement their pain management with psychological tools to overcome the aftereffects of trauma (Dupin et al., 1991; Packard, 1999) . Focused research on mechanisms underlying PTH is necessary for the future development of novel therapies specifically targeting this condition.
Models of PTH-associated Pain
There are a number of limitations associated with modeling headache in animals, especially considering the subjective nature of the disease. Nevertheless, these types of models are necessary to understand the mechanism of PTH and to screen novel drug therapies. Currently, the majority of PTH models focus on assessing nociceptive responses in rodents following some form of TBI. There are numerous models of TBI, and the majority of PTH preclinical studies have used versions that produce a mild to moderate TBI. One thing to keep in mind is that for ethical reasons TBI is induced while the animals are anesthetized. Anesthetics are known to alter cortical networks and pain processing, and this factor should be considered when interpreting the findings. Considering the prevalence of PTH, it is surprising that there are so few preclinical studies investigating this disorder. We summarize the methods and findings below and in Table I .
Lateral fluid percussion model. In this model, mTBI is induced through a wave of pressure applied onto the dura. Following craniotomy, a fluid percussion device is placed against the dura, and a wave of fluid is rapidly propagated through the device when a metal pendulum strikes a piston filled with saline (McIntosh et al., 1989) . A detailed video of this procedure can be found in Alder et al. (2011) . An increase in mechanical, but not thermal, allodynia in the contralateral hindpaw was observed for up to 72 hr following unilateral, lateral fluid percussion. This increase was associated with a concomitant upregulation in brain-derived neurotrophic factor (BDNF) mRNA and protein expression in the contralateral spinal cord (Feliciano et al., 2014) . It has been previously shown that in models of dural inflammation, both cranial and hindpaw hypersensitivity is observed (Edelmayer et al., 2012; De Felice et al., 2013) ; therefore, in rodents, disruption of the dura may sensitize pain mechanisms at peripheral sites. In addition, both cephalic and extracephalic allodynia has been observed in patients with chronic pain due to TBI (Ofek and Defrin, 2007) . It has yet to be determined whether the allodynia observed after the lateral fluid percussion injury is representative of chronic peripheral pain associated with mTBI or a correlate to PTH.
Closed-head weight-drop model. The closedhead weight-drop model is one of the few mTBI models in which the skull and scalp are kept intact (Zohar et al., 2003) . Briefly, anesthetized mice are positioned under a vertical metal guide tube, and a cylindrical-shaped iron weight with a slight spherical tip is dropped from the full length of the tube onto one side of the mouse head. With the advantage of minimal damage to the intact crania, this mild closed-head injury produces long-lasting learning and memory impairments, while keeping brain morphology intact (Zohar et al., 2003) . With regard to PTH, this type of mTBI produced increased pain sensitivity to low doses of formalin injected into cranial tissue innervated by the trigeminal nerve. Interestingly, this heightened response was not observed with formalin in the hindpaw, indicative of a head-specific pain (Benromano et al., 2015) . These studies were performed 48 hr after head injury, and it will be interesting to see if alterations in pain sensitivity persist at longer time points.
In a study using rats, a different closed-head weightdrop model (Marmarou et al., 1994) was used to examine changes in pain-related behaviors in an operant testing paradigm. In this model, mTBI is induced by attaching a metal plate to the exposed cranium and dropping a 450-g weight from a height of 1.25 m onto the plate. This technique is considered a model of mild vs. moderate/severe TBI, as the metal disk diffuses the force of the weight and decreases the probability of skull fracture (Marmarou et al., 1994) . Two weeks post injury, rats were tested in a reward-conflict test where the animal could choose to obtain a sweetened milk reward by pressing its face through plates that were warmed or cooled to produce varying levels of thermal nociception (Neubert et al., 2005) . This pain test is thought to better model the human pain condition, as both the nociceptive and emotional components of pain are examined. Post injury, rats showed decreased facial contact and lick behaviors to either warm or cool temperatures. This heightened thermal sensitivity was accompanied by an augmentation in the pain-processing molecules: serotonin, norepinephrine, GABA, and the substance P receptor (NK1R) in the somatosensory cortex, thalamus, and trigeminal nucleus caudalis (Mustafa et al., 2016) . This study indicates that mTBI produces heightened facial pain sensitivity and/or decreased motivational drive, two factors that are also symptomatic of the human headache experience. Furthermore, this study also shows that injury at the level of the cortex produces adaptations in pain-processing regions distal to the site of injury. Controlled cortical impact model. The controlled cortical impact (CCI) model is one of the most frequently used and best-characterized models of TBI (Xiong et al., 2013; Petraglia et al., 2014) . This is a model of focal TBI and is highly reproducible across animals. Following a unilateral craniotomy, a controlled impact is applied to the intact dura with an electromagnetic or pneumatic impactor (Lighthall, 1988) . A video showing the detailed CCI procedure can be found in Romine et al. (2014) . In a series of elegant studies by Elliott's lab, increased head pain sensitivity was observed following CCI. In these experiments, mice showed increased mechanical allodynia in the periorbital region, both ipsiand contralateral to the site of injury. Although peak nociception was observed 14 days following injury, allodynia persisted for up to 28 days post TBI (Elliott et al., 2012; Daiutolo et al., 2016) . To support that this nociception was associated with PTH, two migraine medications-sumatriptan and the calcitonin gene-related peptide (CGRP) antagonist MK8825-blocked CCIinduced periorbital allodynia (Daiutolo et al., 2016) . Furthermore, CCI also produced photophobia (Daiutolo et al., 2016) , another frequently observed symptom of migraine (Rossi and Recober, 2015) . Interestingly, this group also found that periorbital allodynia was more pronounced in mice than rats following CCI, and that at earlier time points peripheral forepaw mechanical allodynia was also observed . Compared with the clinical experience of mTBI, the CCI model is more severe, involving a craniotomy and a high-pressure impact to a focal cortical region. However, this series of studies shows a number of links between head trauma and posttraumatic migraine, especially in terms of the chronicity and response to migraine-specific pharmacotherapies. Considering that PTH has so few preclinical tools, for the time being CCI is the best-characterized model to screen for novel therapies.
Cell-based in vitro model of bTBI. Animal models are not ideal for the high-throughput screening techniques required for drug discovery, and to address this issue a cell-based bTBI model was recently developed (Arun et al., 2011) . The in vitro bTBI model consists of using a compressed air-driven shock tube and mouse neuroblastoma/rat glioblastoma hybrid (NG108-15) or SH-SY5Y human neuroblastoma cells in tissue culture plates. Upon blast exposure, cells demonstrated significant cellular injury, with the highest damage resulting from one blast exposure instead of repeated blast exposures. Cells expressed a significant depletion of intracellular ATP levels and increased reactive oxygen species formation, correlating with in vivo findings from prior literature (Arun et al., 2011) . Theoretically, this in vitro system could be used to study complex cell-specific responses to blast injury and may be used to initially screen pharmacotherapies for TBI and PTH. An interesting adaptation would be to use nonneoplastic cells to avoid differential protein expression and metabolic processing associated with cancer cells.
Proposed Mechanisms Underlying the Development of PTH
Neuroinflammation. Inflammation is rapidly elicited in response to brain injury, and neuroinflammatory mechanisms have been well characterized in TBI (Mayer et al., 2013; Gyoneva and Ransohoff, 2015) . In the brain, TBIs disturb ionic and neurotransmitter homeostasis and neurovascular processes and result in cell injury and/or cell death (Ziebell and Morganti-Kossmann, 2010) . Similar biochemical changes in people suffering from mTBI and migraine have been noted, suggesting a shared mechanism (Solomon, 1998 (Solomon, , 2009 ). Inflammatory mediators have been at the crux of preliminary studies investigating PTH. Immediately after TBI, the immune system recruits various cell types to combat injury-induced disturbances, including mast cells, microglia, astrocytes, and inflammatory cytokines. This neuroinflammatory response can ultimately trigger sensitization of the trigeminovascular complex resulting in PTH. In addition, cortical injury can trigger inflammatory responses in deeper neuroanatomical structures, including the thalamus (Hazra et al., 2014) , a region that is also important for migraine-associated pain (Burstein et al., 2010) .
The dura mater is heavily innervated by pain fibers and is also densely populated by immune cells (Dimlich et al., 1991) . Among the immune cells are mast cells, which are granulated cells that reside parallel to trigeminal nerve branches in the inner layer of the dura (Dimlich et al., 1991) . Upon activation, mast cells release histamine and proinflammatory cytokines such as interferon gamma and tumor necrosis factor alpha (TNFa), all of which can encourage a pronociceptive state. Early work demonstrated that dural mast cells play a role in neuroinflammatory responses to injury as well as to headache (Dimlich et al., 1991) . In vivo electrophysiological recordings also showed that degranulation of dural mast cells induced a prolonged state of excitation in rat meningeal nociceptors (Levy et al., 2007) . This excitation was accompanied by increased expression of the phosphorylated form of the extracellular signal-regulated kinase, a marker for nociceptor activation, and an increase in c-fos expression in the spinal trigeminal nucleus (Levy et al., 2007) . Peak mast cell degranulation was observed 72 hr post trauma in a closed-head weight-drop model, and at 30 days in a bTBI model (Levy et al., 2016) . Interestingly, acute treatment with sumatriptan, a migraine-specific medication, did not reduce dural mast cell degranulation at 7 or 30 days post injury, which suggests an alternative mode of action for this drug (Levy et al., 2016) .
Microglia also play a key role in the initiation and prolongation of neuroinflammation (Nimmerjahn et al., 2005; Mayer et al., 2013) . Residing in the CNS, microglia monitor pathogens within the intraparenchymal space and are activated following injury (Nimmerjahn et al., 2005 ). An imbalance of microglial activation could result in continued release of cytotoxic inflammatory mediators, including reactive oxygen species and nitric oxide, contributing to progression of headache symptoms (Olesen, 2008; Loane and Byrnes, 2010) . Aberrant microglial activation has been associated with many central nervous system disorders, including chronic pain (Ji et al., 2013; Grace et al., 2014; Taylor et al., 2016) . Increased microglial and astrocyte activation was observed in the somatosensory cortex following CCI (Elliott et al., 2012) . Peak activation preceded peak periorbital allodynia (7 vs. 14 days), and microglial activation may be an early event that contributes to nociceptor sensitization resulting in PTH.
Numerous inflammatory mediators and cytokines are associated with TBI (Gyoneva and Ransohoff, 2015) . Cytokines have both pro-and anti-inflammatory effects depending on environmental factors (Ziebell and Morganti-Kossmann, 2010) . For example, interleukin-1b (IL-1b) is a proinflammatory marker that is elevated within hours post TBI (Winter et al., 2002) and acts to promote the release of other cytokines, including TNFa (Ziebell and Morganti-Kossmann, 2010) . In a CCI model, an increase in TNFa mRNA expression was found at 6 hr, 1 day, and 3 days post trauma (Amenta et al., 2014) . Furthermore, the synergistic relationship between IL-1b and TNFa results in increased permeability of the bloodbrain barrier and is an important process in the initiation and maintenance of other pain states (Alves, 2014) .
The integrity of the blood-brain barrier is often compromised following TBI both because of the actual injury and subsequent release of proinflammatory cytokines. Matrix metalloproteinases (MMPs) are a group of endopeptidase enzymes involved with the degradation of extracellular matrix proteins, and thus mediate bloodbrain barrier permeability (Rempe et al., 2016) . MMPs regulate extracellular matrix turnover and have been implicated in brain injuries (Lakhan and Avramut, 2012) . Synthesis of MMPs increases to promote local repair in response to neuronal injuries, but in parallel also contributes to the permeation of the blood-brain barrier. Levels of MMP-2 and MMP-9 have been shown to be elevated post TBI (Zhang et al., 2016) , as well as in patients with migraine (Imamura et al., 2008; Lakhan and Avramut, 2012) . Interestingly, cortical spreading depression, a phenomenon related to migraine pathogenesis and aura, and observed following TBI, has also been shown to increase levels of MMP-9 (Imamura et al., 2008; Lakhan and Avramut, 2012) .
Migraine-associated neuropeptides and PTH. The neuropeptide CGRP is a well-characterized biomarker of migraine, and mTBI could increase migraine susceptibility through this mechanism. CGRP is upregulated in blood plasma and saliva during a migraine attack (Goadsby et al., 1990 ) and interictally in chronic migraine patients (Cernuda-Morollon et al., 2013) . CGRP is also a known migraine trigger when administered intravenously (Lassen et al., 2002) . CGRP has multiple sites of action within the trigeminovascular complex, spinal cord, and brain (Eftekhari et al., 2015) . CGRP release at nerve terminals contributes to neurogenic inflammation by increasing vasodilation and mast cell degranulation, and activation of CGRP receptors in the brain stem can produce allodynia and central sensitization (Bigal et al., 2013) . CGRP antagonists are effective migraine treatments (Ho et al., 2010; Bigal et al., 2013; Karsan and Goadsby, 2015) , and antibodies targeting CGRP or its receptor are currently being tested as migraine therapies (Bigal et al., 2015) . CGRP may act as a link between brain injury and the development of PTH. To support this facilitatory role of CGRP, TBI induced by CCI has been shown to augment CGRP expression (Elliott et al., 2012; Theeler et al., 2013) and is part of a neuroinflammatory process that includes activation of inducible nitric oxide synthase initiated in response to injury. Using a CCI model of TBI, a significant increase in CGRP levels was observed in the brain stem of CCI mice compared with control craniotomy counterparts (Elliott et al., 2012) . This focal injury to the sensory cortex increased protein expression of CGRP in the trigeminovascular system for up to 2 weeks post injury (Daiutolo et al., 2016) . In addition, the migraine medication sumatriptan reduced this upregulation. Furthermore, the CGRP antagonist MK8825 inhibited both periorbital allodynia and photosensitivity evoked by CCI injury. These results suggest that upcoming CGRP-targeted therapies will be promising for the future treatment of PTH.
Pituitary adenylate cyclase-activating polypeptide (PACAP) is emerging as a key player in migraine pathophysiology. PACAP is a potent vasodilator of meningeal and trigeminal ganglia arteries and, like CGRP, is a known migraine trigger. In addition, inhibition of a PACAP receptor, PAC1, attenuated electrophysiological activity associated with dural nociception (Akerman and Goadsby, 2015) . Increased levels of PACAP in cerebrospinal fluid and plasma have also been observed following severe TBI (Bukovics et al., 2014) . Further, PACAP also regulates cellular stress responses, and increased PACAP levels have been correlated with increased PTSD symptoms (Theeler et al., 2013) . PTH and PTSD are often comorbid, especially in the military population, and PTSD appears to augment the severity of PTH (Theeler et al., 2013 ). PACAP appears to be another convergent point by which mTBI could lead to posttraumatic migraine. In a closed-head weight-drop model, exogenous administration of PACAP was found to be neuroprotective, and treatment with PACAP38 inhibited mTBI-induced upregulation of toll-like receptor 4 and its downstream signaling molecules-important mediators of neuroinflammation. Further, PACAP38 also blocked the increase in levels of downstream inflammatory agents IL1b and TNF-a, in the brain tissue at and near the injury site (Mao et al., 2012) , and PACAP activation may also protect from injury-induced oxidative stress (Miyamoto et al., 2014) . In addition, the neuropeptide substance P (Elliott et al., 2012; Corrigan et al., 2016; Mustafa et al., 2016) and the growth factor BDNF (Kaplan et al., 2010; Feliciano et al., 2014) have also been implicated in TBI.
There is an interaction between TBI and migraine, and further research into the factors mediating each condition could provide valuable insight on overlapping mechanisms shared by both conditions.
CONCLUSIONS AND FUTURE DIRECTIONS
Many preclinical studies have been performed to investigate the pathophysiology of TBI. However, considering that PTH is the leading symptom of TBI, surprisingly little research has been done to understand how mTBI results in PTH. PTH often persists long after mTBI, and this suggests that the trigeminal nociceptive pathway is primed by neuroinflammatory and allostatic events triggered by injury. For the time being, our understanding of the complex mechanism regulating PTH remains limited. Deeper insight into the neurotransmitters, inflammatory mediators, and cellular and circuit adaptations that occur after mTBI, and how they relate to migraine, is critical to reveal novel therapeutic targets for PTH. A greater emphasis needs to be placed on the further characterization of already-existing animal models and on the development of new animal models of PTH. In addition, in vitro models reflecting brain cell-specific changes that occur following trauma could be a promising strategy for high-throughput screening of emerging therapies. Furthermore, repetitive TBI has recently received a lot of attention in sports and the military, and animal models have been developed to study this type of injury (Kane et al., 2012; Semple et al., 2015; McAteer et al., 2016; Ojo et al., 2016; Winston et al., 2016) . Future preclinical studies focused on the effect of repetitive TBI on PTHassociated symptoms would provide much needed insight on how the brain's pain-processing regions adapt to repeated injury. Overall, a greater emphasis on wellcharacterized animal models of PTH would allow for the investigation of molecular mechanisms regulating this disorder, and subsequent rational drug design.
